Association of BRCA1/2, homologous recombination deficiency, and PD-L1 with clinical outcomes in patients receiving atezolizumab versus placebo combined with carboplatin, paclitaxel, and bevacizumab for newly diagnosed ovarian cancer: exploratory analyses of IMagyn050/GOG3015/ENGOT-ov39
Year: 2021
Type: article
Source: Gynecologic Oncology
Authors: Charles Landen, Luciana Molinero, Jalid Sehouli, Austin Miller, Kathleen Moore, Cagatay Taskiran, Michael Bookman, Kristina Lindemann, Charles Anderson, Regina Berger, Tashanna Myers, Mario Beiner, Thomas Reid, Els Van Nieuwenhuysen, Andrew Green, Aikou Okamoto, Carol Aghajanian, Premal Thaker, Stephanie Blank, Victor Khor, Fan Wu, Yvonne Lin, Sandro Pignata
Institutions: University of Virginia, Genentech, Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie, Charité - Universitätsmedizin Berlin, Roswell Park Comprehensive Cancer Center, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Koç University, Amerikan Hastanesi, Gynecologic Oncology Group, Kaiser Permanente Northern California, Oslo University Hospital, University of Oslo, Willamette Valley Cancer Institute and Research Center, Innsbruck Medical University, AGO Austria, Baystate Medical Center, Tel Aviv University, Meir Medical Center, Kettering Medical Center, Universitair Ziekenhuis Leuven, Northeast Georgia Medical Center, Jikei University School of Medicine, Memorial Sloan Kettering Cancer Center, Washington University in St. Louis, Icahn School of Medicine at Mount Sinai, Roche (China), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3194553091